广生堂（300436.SZ）12月3日在投资者互动平台表示，尊敬的投资者，您好！GST-HG141的III期临床试 验是一项48周治疗的随机双盲研究，是公司创新药研发管线的重点项目，正按计划全力推进。为确保数 据的完整性，公司目前暂未安排该试验中期揭盲分析计划。公司将持续高效推进试验进程并及时披露创 新药重大进展，感谢您的关注和支持！ （记者 曾健辉） 每经AI快讯，有投资者在投资者互动平台提问：请问广生堂141三期临床会不会出中期数据？如果会的 话大概在什么时候出？ ...

Core Viewpoint - Guangshentang experienced a decline of 5.01% on December 2, with a stock price of 94.54 CNY per share and a total market capitalization of 15.057 billion CNY [1] Company Overview - Fujian Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015 [1] - The company's main business involves the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications and 1.46% from other supplementary products [1] Fund Holdings - Jin Xin Fund has one fund heavily invested in Guangshentang, specifically the Jin Xin Value Selection Mixed A (005117), which held 11,000 shares, accounting for 3.65% of the fund's net value, ranking as the eighth largest holding [2] - The fund has experienced a floating loss of approximately 54,900 CNY today [2] Fund Performance - Jin Xin Value Selection Mixed A (005117) was established on September 1, 2017, with a current scale of 13.4048 million CNY [2] - Year-to-date return is 52.18%, ranking 741 out of 8122 in its category; the one-year return is 47.38%, ranking 869 out of 8056; and since inception, the return is 70.76% [2] Fund Manager Information - The fund managers are Liu Shang and Tan Zhiming, with Liu having a tenure of 102 days and a total fund size of 109 million CNY, while Tan has a tenure of 237 days with a total fund size of 141 million CNY [3] - Liu's best and worst fund returns during his tenure are -7.2% and -14.03%, respectively, while Tan's best and worst returns are 33.16% and -2.98% [3]

关于选举第五届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司章 程指引》《关于新＜公司法＞配套制度规则实施相关过渡期安排》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》（等有关法律、法规和规范性文件的规定，结合公司 实际情况，公司于 2025 年 11 月 21 日召开了 2025 年第三次临时股东大会，审议 通过了《关于修订＜公司章程＞的议案》，根据修订后的《福建广生堂药业股份 有限公司章程》（以下简称"《公司章程》"），董事会由 9 名董事组成，设董 事长 1 人，独立董事 3 人，职工代表董事 1 人。 公司于 2025 年 11 月 21 日召开了职工代表大会，经与会职工代表认真讨论， 一致同意选举欧阳昭权先生（简历详见附件）为公司第五届董事会职工代表董事， 与其他现任董事共同组成公司第五届董事会，任期自本次职工代表大会选举通过 之日起至第五届董事会任期届满之日止。 欧阳昭权先生符合《公司法》等 ...

证券代码：300436 证券简称：广生堂 公告编号：2025076 福建广生堂药业股份有限公司 关于 2025 年第三次临时股东大会决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开时间： 1、现场会议召开时间：2025 年 11 月 21 日（星期五）14:30 2、网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 11 月 21 日 9:15—9:25，9:30—11:30 和 13:00—15:00。 （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 11 月 21 日 9:15—15:00。 （二）现场会议召开地点：福建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园二期 16 号楼 13F 会议室 （三）会议召集人：公司董事会 （四）会议主持人：董事长李国平先生 （五）会议召开方式：现场表决与网络投票相结合的方式 （六）会 ...

国浩律师（上海）事务所 关 于 福建广生堂药业股份有限公司 2025 年第三次临时股东大会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 二零二五年十一月 国浩律师（上海）事务所 关于福建广生堂药业股份有限公司 2025 年第三次临时股东大会之法律意见书 致：福建广生堂药业股份有限公司 福建广生堂药业股份有限公司（以下简称"公司"）2025 年第三次临时股东 大会于 2025 年 11 月 21 日召开。国浩律师（上海）事务所（以下简称"本所"） 经公司聘请，委派律师出席现场会议，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"） 等法律、法规及中国证券监督 ...

Group 1 - The core point of the article highlights the recent performance of Guangshentang, which saw a 5.03% increase in stock price, reaching 109.55 CNY per share, with a trading volume of 812 million CNY and a turnover rate of 5.70%, resulting in a total market capitalization of 17.448 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is based in Fuzhou, Fujian Province, and specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund, specifically the China Europe Medical Health Mixed A (003095), reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares, with an estimated floating profit of approximately 3.7178 million CNY [2] - The China Europe Medical Health Mixed A fund was established on September 29, 2016, with a current scale of 16.977 billion CNY, achieving a year-to-date return of 21.25% and a one-year return of 8.97% [2]

Group 1 - The core viewpoint of the news is that Guangshentang's stock price increased by 5.82%, reaching 108.92 CNY per share, with a trading volume of 916 million CNY and a turnover rate of 6.61%, resulting in a total market capitalization of 17.347 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under China Europe Fund ranks among Guangshentang's top shareholders. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The estimated floating profit for the China Europe Medical Health Mixed A Fund today is approximately 4.2418 million CNY [2] - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, with a latest scale of 16.977 billion CNY. Year-to-date returns are 21.33%, ranking 4326 out of 8147 in its category, while the one-year return is 10.73%, ranking 5278 out of 8056 [2]

Investment Rating - The report does not explicitly state an investment rating for the industry [1] Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.4% from November 3 to November 7, 2025, underperforming compared to the Wind All A index (0.63%) and the CSI 300 index (0.82%) [2][7] - The rise in flu activity was noted, with the percentage of flu-like illness (ILI) cases reported at 4.7% in the week of October 27 to November 2, 2025, indicating an increase compared to previous weeks and years [2][10] - The final overall survival (OS) results from the HARMONi-A study of Ivosidenib combined with chemotherapy for EGFR-mutant non-small cell lung cancer showed a significant improvement in OS, with a median OS of 16.8 months versus 14.1 months for the control group [2][10] Weekly Market Review - The pharmaceutical and biotechnology sector's performance was down 2.4%, with notable declines in medical research outsourcing (-4.93%), chemical preparations (-4.42%), and other biological products (-4.33%) [7][8] - The leading gainers included Hezhi China (61.1%), Wanze Shares (30.3%), and Fuxiang Pharmaceutical (23.3%), while Changshan Pharmaceutical (-20%), Yifang Bio-U (-17.8%), and Guangshengtang (-15.3%) were the biggest losers [10] Industry News and Key Company Announcements - On November 7, 2025, the final OS analysis of the HARMONi-A study was presented, showing significant results for Ivosidenib in combination with chemotherapy [10][12] - According to data from the Chinese Center for Disease Control, flu-like illness percentages in southern provinces increased to 4.6%, while northern provinces reported 5.1%, both higher than the previous week [10][12] - BeiGene reported a total revenue of $1.412 billion for Q3 2025, a 41% year-on-year increase, driven by a 51% growth in global sales of its product [12][14] - Metsera announced a merger agreement with Pfizer, with an estimated total transaction value of approximately $9 billion [12][14]

Group 1 - The core point of the news is that Guangshentang's stock price dropped by 5.09% to 102.88 CNY per share, with a trading volume of 722 million CNY and a turnover rate of 5.01%, resulting in a total market capitalization of 16.385 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund holds a position. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The estimated floating loss for the China Europe Medical Health Mixed A Fund today is approximately 3.909 million CNY. The fund was established on September 29, 2016, with a latest scale of 16.977 billion CNY, and has achieved a year-to-date return of 21.69% [2] - The fund's one-year return is 13.44%, ranking 5002 out of 8053 in its category, while since its inception, it has achieved a return of 110.03% [2]

Core Viewpoint - Guangshentang's stock price has shown significant volatility, with a year-to-date increase of 231.65%, but recent performance indicates a slight decline in the short term [1][2]. Group 1: Stock Performance - As of November 6, Guangshentang's stock price rose by 2.02% to 108.35 CNY per share, with a trading volume of 6.42 billion CNY and a turnover rate of 4.41%, resulting in a total market capitalization of 17.257 billion CNY [1]. - The stock has experienced a 1.40% decline over the last five trading days, a 14.05% increase over the last 20 days, and a 6.15% decline over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on July 31 [1]. Group 2: Financial Performance - For the period from January to September 2025, Guangshentang reported a revenue of 316 million CNY, reflecting a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of -112 million CNY, a decline of 57.96% year-on-year [2]. - The company has cumulatively distributed dividends of 84.6485 million CNY since its A-share listing, with no dividends paid in the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Guangshentang increased to 45,800, a rise of 125.95%, while the average number of tradable shares per shareholder decreased by 55.74% to 2,985 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest with 1.7463 million shares, marking its entry as a new shareholder [3].